For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associ ...

A study published in the American Journal of Ophthalmology suggests that the use of SGLT2 inhibitors in diabetes is linked to ...

A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

NEW research has revealed that sodium-glucose cotransporter 2 inhibitors (SGLT2is) are associated with an 18% reduction in ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are a relatively new group of medications originally developed ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

In patients without cirrhosis, GLP-1 RA use was associated with a 14% lower risk of developing cirrhosis than DPP-4 inhibitor use (9.98 vs 11.1 events per 1000 person-years). In this group ...

dipeptidyl-peptidase-4 inhibitors (DPP-4i), and other GLP-1RAs (which mimic the effects of GLP-1s). Patients prescribed semaglutide had a 40% to 70% reduced risk of first-time Alzheimer’s ...